Manejo de los efectos adversos del tratamiento de la hepatitis C

González Ballerga, Esteban; Fernández, Nora; Losso, Marcelo.
Acta gastroenterol. latinoam ; 36(supl. 1): S61-S64, jun. 2006. tab
Artículo en Español | BINACIS | ID: bin-123380

Documentos relacionados

  1. [Management of adverse effects of hepatitis C treatment].
  2. A case of successful treatment of a rare retinal disease presented by interferon-induced retinopathy.
  3. The Severity of Depressive Symptoms as an Independent Predictor of Sustained Virological Response During Treatment of Hepatitis C With Pegylated Interferon-α2a and Oral Ribavirin.
  4. Hepatitis C virus infection: looking for interferon free regimens.
  5. Interferon-alpha induced psoriasis in a teenager.
  6. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
  7. Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study.
  8. Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin.
  9. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients.
  10. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.